Our results suggest that Orai1 and the downstream calmodulin/calcineurin/NFATC1/COL1A1 signaling pathway may play an important role in PTH-induced endothelial dysfunction and may be key potential therapeutic targets for preventing or treating SHPT-induced CVD. This evidence concerns the gene NFATC1 and endothelial dysfunction.